The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

The article on “UK consensus group calls for biomarker testing at point of diagnosist” has been published in the Cancer World online magazine (Sep, 2022).

In the article, Mark Lawler (CDDF, UK), comments on the consensus statement, saying, “I welcome the conclusions of this consensus group, which offers a pragmatic approach by focusing on what can practically be achieved in real-world settings, as opposed to aspirational targets only achievable in clinical trials and research studies.”

Read the full text here: UK consensus group calls for biomarker testing at point of diagnosis

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70